
Relmada Therapeutics RLMD
$ 0.3
-4.68%
Quarterly report 2024-Q3
added 11-07-2024
Country |
![]() |
IPO year |
- |
Industry |
Drug manufacturers |
Stock Exchange |
NASDAQ GLOBALSPB |
CEO |
Mr. Sergio Traversa |
Employees in the company |
6 |
Shares |
30.1 M |
Market Cap[1] |
$ 9.03 M |
EBITDA (LTM) |
$ -165 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Drug manufacturers"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.